Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

14.67 +0.96 (+7.00%)

Streaming Delayed Price Updated: 11:20 AM EDT, Apr 8, 2026 Add to My Watchlist

Price and Volume

Volume	735,257
Open	15.00
Bid (Size)	14.63 (200)
Ask (Size)	14.68 (200)
Prev. Close	13.71
Today's Range	14.45 - 15.61
52wk Range	6.706 - 20.76
Shares Outstanding	144,311,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On ↗

Today 9:33 EDT

This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider sale.

Via The Motley Fool

Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look ↗

March 30, 2026

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock gains.

Via The Motley Fool

Performance

YTD	-7.8%	-7.8%
1 Month	-1.9%	-1.9%
3 Month	-8.9%	-8.9%
6 Month	+2.2%	+2.2%
1 Year	+90.4%	+90.4%

More News

Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year ↗

March 26, 2026

Via The Motley Fool

Adaptive Biotechnologies (NASDAQ:ADPT) Reports Strong Q4 Revenue Beat and Path to Profitability ↗

February 05, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price ↗

March 26, 2026

Via The Motley Fool

Adaptive Biotech (ADPT) Earnings Call Transcript ↗

February 05, 2026

Via The Motley Fool

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

February 05, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

January 27, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

January 22, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization

January 13, 2026

Via MarketMinute

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

January 12, 2026

From Adaptive Biotechnologies

Via GlobeNewswire

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

December 30, 2025

Via MarketMinute

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 30, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

December 15, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

December 09, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

December 06, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

November 24, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

November 06, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

November 05, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗

November 04, 2025

Via Benzinga

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

October 15, 2025

From Adaptive Biotechnologies

Via GlobeNewswire

Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday ↗

October 13, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Adaptive Biotechnologies Through 4 Analysts ↗

September 30, 2025

Via Benzinga

United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗

September 30, 2025

Via Benzinga

Frequently Asked Questions

Is Adaptive Biotechnologies Corporation - Common Stock publicly traded?

Yes, Adaptive Biotechnologies Corporation - Common Stock is publicly traded.

What exchange does Adaptive Biotechnologies Corporation - Common Stock trade on?

Adaptive Biotechnologies Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Adaptive Biotechnologies Corporation - Common Stock?

The ticker symbol for Adaptive Biotechnologies Corporation - Common Stock is ADPT on the Nasdaq Stock Market

What is the current price of Adaptive Biotechnologies Corporation - Common Stock?

The current price of Adaptive Biotechnologies Corporation - Common Stock is 14.67

When was Adaptive Biotechnologies Corporation - Common Stock last traded?

The last trade of Adaptive Biotechnologies Corporation - Common Stock was at 04/08/26 11:20 AM ET

What is the market capitalization of Adaptive Biotechnologies Corporation - Common Stock?

The market capitalization of Adaptive Biotechnologies Corporation - Common Stock is 2.12B

How many shares of Adaptive Biotechnologies Corporation - Common Stock are outstanding?

Adaptive Biotechnologies Corporation - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.